X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with J.B.Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs J.B.CHEMICALS - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

J.B.CHEMICALS 
   Change

JB Chemicals and Pharmaceuticals Limited (JBCPL), the flagship of the Unique Group, is one of the India's leading transnational pharmaceutical company. The company has 11 manufacturing facilities at four locations in India (Belapur, Ankleshwar, Panol... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS J.B.CHEMICALS NOVARTIS/
J.B.CHEMICALS
 
P/E (TTM) x 321.8 17.4 1,852.4% View Chart
P/BV x 35.7 2.4 1,516.6% View Chart
Dividend Yield % 1.3 0.2 777.7%  

Financials

 NOVARTIS   J.B.CHEMICALS
EQUITY SHARE DATA
    NOVARTIS
Mar-18
J.B.CHEMICALS
Mar-16
NOVARTIS/
J.B.CHEMICALS
5-Yr Chart
Click to enlarge
High Rs758318 238.3%   
Low Rs579200 290.2%   
Sales per share (Unadj.) Rs228.4148.0 154.3%  
Earnings per share (Unadj.) Rs31.719.1 166.3%  
Cash flow per share (Unadj.) Rs32.823.9 136.8%  
Dividends per share (Unadj.) Rs10.000.50 2,000.0%  
Dividend yield (eoy) %1.50.2 774.3%  
Book value per share (Unadj.) Rs297.1128.9 230.4%  
Shares outstanding (eoy) m24.6984.82 29.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.91.7 167.4%   
Avg P/E ratio x21.113.6 155.3%  
P/CF ratio (eoy) x20.410.8 188.8%  
Price / Book Value ratio x2.22.0 112.1%  
Dividend payout %31.52.6 1,202.6%   
Avg Mkt Cap Rs m16,50521,951 75.2%   
No. of employees `0000.72.7 24.4%   
Total wages/salary Rs m1,4451,841 78.5%   
Avg. sales/employee Rs Th8,441.34,590.9 183.9%   
Avg. wages/employee Rs Th2,163.6673.4 321.3%   
Avg. net profit/employee Rs Th1,173.1592.1 198.1%   
INCOME DATA
Net Sales Rs m5,63912,551 44.9%  
Other income Rs m1,718542 317.3%   
Total revenues Rs m7,35713,093 56.2%   
Gross profit Rs m-632,055 -3.0%  
Depreciation Rs m25412 6.1%   
Interest Rs m5596 57.8%   
Profit before tax Rs m1,5752,088 75.4%   
Minority Interest Rs m00 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m792469 168.8%   
Profit after tax Rs m7841,619 48.4%  
Gross profit margin %-1.116.4 -6.8%  
Effective tax rate %50.322.5 223.7%   
Net profit margin %13.912.9 107.8%  
BALANCE SHEET DATA
Current assets Rs m9,5227,778 122.4%   
Current liabilities Rs m3,2964,358 75.6%   
Net working cap to sales %110.427.2 405.2%  
Current ratio x2.91.8 161.9%  
Inventory Days Days3755 67.0%  
Debtors Days Days2880 35.5%  
Net fixed assets Rs m465,713 0.8%   
Share capital Rs m123170 72.8%   
"Free" reserves Rs m7,21310,547 68.4%   
Net worth Rs m7,33610,937 67.1%   
Long term debt Rs m00-   
Total assets Rs m11,10515,574 71.3%  
Interest coverage x29.522.8 129.2%   
Debt to equity ratio x00-  
Sales to assets ratio x0.50.8 63.0%   
Return on assets %7.611.0 68.6%  
Return on equity %10.714.8 72.2%  
Return on capital %22.220.0 111.3%  
Exports to sales %048.7 0.0%   
Imports to sales %07.1 0.0%   
Exports (fob) Rs mNA6,115 0.0%   
Imports (cif) Rs mNA889 0.0%   
Fx inflow Rs m616,169 1.0%   
Fx outflow Rs m3,6301,285 282.5%   
Net fx Rs m-3,5704,884 -73.1%   
CASH FLOW
From Operations Rs m1,6101,397 115.3%  
From Investments Rs m687-320 -214.5%  
From Financial Activity Rs m-2,677-1,196 223.8%  
Net Cashflow Rs m-380-102 371.1%  

Share Holding

Indian Promoters % 0.0 55.4 -  
Foreign collaborators % 75.0 0.3 25,000.0%  
Indian inst/Mut Fund % 2.0 3.4 59.0%  
FIIs % 1.6 3.9 41.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 37.0 58.1%  
Shareholders   41,647 30,437 136.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   SUN PHARMA  MERCK LTD  GSK PHARMA  FULFORD INDIA  DR. REDDYS LAB  

Compare NOVARTIS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Close at Record Highs; Healthcare and Power Stocks Witness Buying(Closing)

Indian share markets continued to trade on a flat during closing hours of trade and ended the day marginally higher to close at fresh record high levels.

Related Views on News

NOVARTIS Announces Quarterly Results (1QFY19); Net Profit Up 42.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, NOVARTIS has posted a net profit of Rs 100 m (up 42.2% YoY). Sales on the other hand came in at Rs 1 bn (up 20.3% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY18); Net Profit Up 809.6% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, NOVARTIS has posted a net profit of Rs 265 m (up 809.6% YoY). Sales on the other hand came in at Rs 1 bn (down 13.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Only on WhatsApp, a Weaker Rupee Means a Weaker India(Vivek Kaul's Diary)

Aug 16, 2018

While dollar crossing Rs 70 will have its repercussions, the world isn't exactly coming to an end.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Aug 21, 2018 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS 8-QTR ANALYSIS

COMPARE NOVARTIS WITH

MARKET STATS